A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
Market Analysis and Insights: Global Companion Cancer Diagnostics Market
The global Companion Cancer Diagnostics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Companion Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Companion Cancer Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Companion Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Companion Cancer Diagnostics market.
Companion Cancer Diagnostics Breakdown Data by Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Companion Cancer Diagnostics Breakdown Data by Application
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
Based on regional and country-level analysis, the Companion Cancer Diagnostics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Companion Cancer Diagnostics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
Market Analysis and Insights: Global Companion Cancer Diagnostics Market
The global Companion Cancer Diagnostics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Companion Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Companion Cancer Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Companion Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Companion Cancer Diagnostics market.
Companion Cancer Diagnostics Breakdown Data by Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Companion Cancer Diagnostics Breakdown Data by Application
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
Based on regional and country-level analysis, the Companion Cancer Diagnostics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Companion Cancer Diagnostics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Breast Cancer
1.2.3 Lung Cancer
1.2.4 Colorectal Cancer
1.2.5 Melanoma
1.2.6 Gastric Cancer
1.3 Market by Application
1.3.1 Global Companion Cancer Diagnostics Market Share by Application: 2020 VS 2026
1.3.2 Pharmaceutical & Biopharmaceutical Companies
1.3.3 Reference Laboratories
1.3.4 CROs
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Companion Cancer Diagnostics Market Perspective (2015-2026)
2.2 Global Companion Cancer Diagnostics Growth Trends by Regions
2.2.1 Companion Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Companion Cancer Diagnostics Historic Market Share by Regions (2015-2020)
2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Companion Cancer Diagnostics Players by Market Size
3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2015-2020)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2015-2020)
3.2 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
3.4 Global Companion Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2019
3.5 Key Players Companion Cancer Diagnostics Area Served
3.6 Key Players Companion Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Companion Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Companion Cancer Diagnostics Breakdown Data by Type (2015-2026)
4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2021-2026)
5 Companion Cancer Diagnostics Breakdown Data by Application (2015-2026)
5.1 Global Companion Cancer Diagnostics Historic Market Size by Application (2015-2020)
5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Companion Cancer Diagnostics Market Size (2015-2026)
6.2 North America Companion Cancer Diagnostics Market Size by Type (2015-2020)
6.3 North America Companion Cancer Diagnostics Market Size by Application (2015-2020)
6.4 North America Companion Cancer Diagnostics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Companion Cancer Diagnostics Market Size (2015-2026)
7.2 Europe Companion Cancer Diagnostics Market Size by Type (2015-2020)
7.3 Europe Companion Cancer Diagnostics Market Size by Application (2015-2020)
7.4 Europe Companion Cancer Diagnostics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Companion Cancer Diagnostics Market Size (2015-2026)
8.2 China Companion Cancer Diagnostics Market Size by Type (2015-2020)
8.3 China Companion Cancer Diagnostics Market Size by Application (2015-2020)
8.4 China Companion Cancer Diagnostics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Companion Cancer Diagnostics Market Size (2015-2026)
9.2 Japan Companion Cancer Diagnostics Market Size by Type (2015-2020)
9.3 Japan Companion Cancer Diagnostics Market Size by Application (2015-2020)
9.4 Japan Companion Cancer Diagnostics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Companion Cancer Diagnostics Market Size (2015-2026)
10.2 Southeast Asia Companion Cancer Diagnostics Market Size by Type (2015-2020)
10.3 Southeast Asia Companion Cancer Diagnostics Market Size by Application (2015-2020)
10.4 Southeast Asia Companion Cancer Diagnostics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2015-2020))
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Details
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
11.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.2.5 Agilent Technologies Recent Development
11.3 QIAGEN
11.3.1 QIAGEN Company Details
11.3.2 QIAGEN Business Overview
11.3.3 QIAGEN Companion Cancer Diagnostics Introduction
11.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.3.5 QIAGEN Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Details
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
11.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.4.5 Abbott Laboratories Recent Development
11.5 Almac Group
11.5.1 Almac Group Company Details
11.5.2 Almac Group Business Overview
11.5.3 Almac Group Companion Cancer Diagnostics Introduction
11.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.5.5 Almac Group Recent Development
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Details
11.6.2 Danaher Corporation Business Overview
11.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
11.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.6.5 Danaher Corporation Recent Development
11.7 bioMérieuxSA
11.7.1 bioMérieuxSA Company Details
11.7.2 bioMérieuxSA Business Overview
11.7.3 bioMérieuxSA Companion Cancer Diagnostics Introduction
11.7.4 bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.7.5 bioMérieuxSA Recent Development
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Details
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
11.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.8.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Breast Cancer
1.2.3 Lung Cancer
1.2.4 Colorectal Cancer
1.2.5 Melanoma
1.2.6 Gastric Cancer
1.3 Market by Application
1.3.1 Global Companion Cancer Diagnostics Market Share by Application: 2020 VS 2026
1.3.2 Pharmaceutical & Biopharmaceutical Companies
1.3.3 Reference Laboratories
1.3.4 CROs
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Companion Cancer Diagnostics Market Perspective (2015-2026)
2.2 Global Companion Cancer Diagnostics Growth Trends by Regions
2.2.1 Companion Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Companion Cancer Diagnostics Historic Market Share by Regions (2015-2020)
2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Companion Cancer Diagnostics Players by Market Size
3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2015-2020)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2015-2020)
3.2 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
3.4 Global Companion Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2019
3.5 Key Players Companion Cancer Diagnostics Area Served
3.6 Key Players Companion Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Companion Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Companion Cancer Diagnostics Breakdown Data by Type (2015-2026)
4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2021-2026)
5 Companion Cancer Diagnostics Breakdown Data by Application (2015-2026)
5.1 Global Companion Cancer Diagnostics Historic Market Size by Application (2015-2020)
5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Companion Cancer Diagnostics Market Size (2015-2026)
6.2 North America Companion Cancer Diagnostics Market Size by Type (2015-2020)
6.3 North America Companion Cancer Diagnostics Market Size by Application (2015-2020)
6.4 North America Companion Cancer Diagnostics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Companion Cancer Diagnostics Market Size (2015-2026)
7.2 Europe Companion Cancer Diagnostics Market Size by Type (2015-2020)
7.3 Europe Companion Cancer Diagnostics Market Size by Application (2015-2020)
7.4 Europe Companion Cancer Diagnostics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Companion Cancer Diagnostics Market Size (2015-2026)
8.2 China Companion Cancer Diagnostics Market Size by Type (2015-2020)
8.3 China Companion Cancer Diagnostics Market Size by Application (2015-2020)
8.4 China Companion Cancer Diagnostics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Companion Cancer Diagnostics Market Size (2015-2026)
9.2 Japan Companion Cancer Diagnostics Market Size by Type (2015-2020)
9.3 Japan Companion Cancer Diagnostics Market Size by Application (2015-2020)
9.4 Japan Companion Cancer Diagnostics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Companion Cancer Diagnostics Market Size (2015-2026)
10.2 Southeast Asia Companion Cancer Diagnostics Market Size by Type (2015-2020)
10.3 Southeast Asia Companion Cancer Diagnostics Market Size by Application (2015-2020)
10.4 Southeast Asia Companion Cancer Diagnostics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2015-2020))
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Details
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
11.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.2.5 Agilent Technologies Recent Development
11.3 QIAGEN
11.3.1 QIAGEN Company Details
11.3.2 QIAGEN Business Overview
11.3.3 QIAGEN Companion Cancer Diagnostics Introduction
11.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.3.5 QIAGEN Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Details
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
11.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.4.5 Abbott Laboratories Recent Development
11.5 Almac Group
11.5.1 Almac Group Company Details
11.5.2 Almac Group Business Overview
11.5.3 Almac Group Companion Cancer Diagnostics Introduction
11.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.5.5 Almac Group Recent Development
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Details
11.6.2 Danaher Corporation Business Overview
11.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
11.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.6.5 Danaher Corporation Recent Development
11.7 bioMérieuxSA
11.7.1 bioMérieuxSA Company Details
11.7.2 bioMérieuxSA Business Overview
11.7.3 bioMérieuxSA Companion Cancer Diagnostics Introduction
11.7.4 bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.7.5 bioMérieuxSA Recent Development
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Details
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
11.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2015-2020)
11.8.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
